Vaccination for Lyme disease: cost-effectiveness versus cost and value.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Arthritis & Rheumatism

• Publication date

  2002-06-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1002/ART.10283PMID 12115172
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cost-effectiveness analysis of the Lyme disease vaccine.

  2002cited by this paper
• Contributions of societal and geographical environments to "chronic Lyme disease": the psychopathogenesis and aporology of a new "medically unexplained symptoms" syndrome.

  2002cited by this paper
• Misconceptions about Lyme Disease: Confusions Hiding behind Ill-Chosen Terminology

  2002cited by this paper
• Prevention of Lyme disease: a review of the evidence.

  2001cited by this paper
• Molecular Evidence of Bartonella spp. in Questing Adult Ixodes pacificus Ticks in California

  2001cited by this paper
• The cost-effectiveness of vaccination against Lyme disease.

  2001cited by this paper
• Arthritis following recombinant outer surface protein A vaccination for Lyme disease.

  2001cited by this paper
• Death from inappropriate therapy for Lyme disease.

  2000cited by this paper
• Reactogenicity and immunogenicity of a Lyme disease vaccine in children 2-5 years old.

  2000cited by this paper
• Prevention of Lyme Disease

  2000cited by this paper
• Immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against Lyme disease in children.

  1999cited by this paper
• The cost effectiveness of vaccinating against Lyme disease.

  1999cited by this paper
• Lyme arthritis: lessons learned and to be learned.

  1999cited by this paper
• Alternative vaccination schedules (0, 1, and 6 months versus 0, 1, and 12 months) for a recombinant OspA Lyme disease vaccine.

  1999cited by this paper
• A cluster of transfusion-associated babesiosis cases traced to a single asymptomatic donor.

  1999cited by this paper
• Pitfalls in the diagnosis and management of Lyme disease.

  1998cited by this paper
• Human Exposure to a Granulocytic Ehrlichia and Other Tick-Borne Agents in Connecticut

  1998cited by this paper
• The Consequences of Overdiagnosis and Overtreatment of Lyme Disease: An Observational Study

  1998cited by this paper
• Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis.

  1998cited by this paper
• Human babesiosis.

  1998cited by this paper
• Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group.

  1998cited by this paper
• Cosegregation of a novel Bartonella species with Borrelia burgdorferi and Babesia microti in Peromyscus leucopus.

  1998cited by this paper
• A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium.

  1998cited by this paper
• Borrelia burgdorferi genes selectively expressed in ticks and mammals.

  1997cited by this paper
• Perspectives Series: Host/Pathogen Interactions Arthropod- and Host-specific Gene Expression by Borrelia burgdorferi

  1997cited by this paper
• Lyme disease: a review of aspects of its immunology and immunopathogenesis.

  1997cited by this paper
• Clinical and laboratory characteristics of human granulocytic ehrlichiosis.

  1996cited by this paper
• Dominant recognition of a Borrelia burgdorferi outer surface protein A peptide by T helper cells in patients with treatment-resistant Lyme arthritis

  1996cited by this paper
• Immunoserologic evidence of coinfection with Borrelia burgdorferi, Babesia microti, and human granulocytic Ehrlichia species in residents of Wisconsin and Minnesota

  1996cited by this paper
• The Lyme disease controversy : Social and financial costs of misdiagnosis and mismanagement

  1996cited by this paper
• Misdiagnosis of Lyme disease: when not to order serologic tests.

  1996cited by this paper
• Ixodes dammini as a potential vector of human granulocytic ehrlichiosis.

  1995cited by this paper
• Ehrlichial Diseases of Humans: Emerging Tick-Borne Infections

  1995cited by this paper
• Biliary complications in the treatment of unsubstantiated Lyme disease.

  1995cited by this paper
• Safety and immunogenicity of an outer surface protein A vaccine in subjects with previous Lyme disease.

  1995cited by this paper
• Ehrlichial diseases of humans: emerging tick-borne infections.

  1995cited by this paper
• Persisting complaints attributed to chronic Lyme disease: possible mechanisms and implications for management.

  1994cited by this paper
• Empirical Parenteral Antibiotic Treatment of Patients with Fibromyalgia and Fatigue and a Positive Serologic Result for Lyme Disease: A Cost-Effectiveness Analysis

  1993cited by this paper
• Empiric parenteral antibiotic treatment of patients with fibromyalgia and fatigue and a positive serologic result for Lyme disease. A cost-effectiveness analysis.

  1993cited by this paper
• The overdiagnosis of Lyme disease.

  1993cited by this paper
• Association of treatment-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB of Borrelia burgdorferi

  1993cited by this paper
• The biological and social phenomenon of Lyme disease.

  1993cited by this paper
• Elimination of Borrelia burgdorferi from vector ticks feeding on OspA-immunized mice.

  1992cited by this paper
• ASSOCIATION OF CHRONIC LYME ARTHRITIS WITH HLA‐DR4 and HLA‐DR2 ALLELES

  1990cited by this paper
• Summary of the first 100 patients seen at a Lyme disease referral center.

  1990cited by this paper
• Medical progress. Lyme disease

  1989cited by this paper
• Lyme disease.

  1989cited by this paper
• Cases of Lyme disease in the United States: locations correlated with distribution of Ixodes dammini.

  1979cited by this paper

• A systematic review and meta-analysis for the adverse effects, immunogenicity and efficacy of Lyme disease vaccines: Guiding novel vaccine development

  2017cites this paper
• Pricing of new vaccines

  2010cites this paper
• Management of Lyme disease

  2008cites this paper
• Strategies for primary and secondary prevention of Lyme disease

  2007cites this paper
• Cost-effectiveness analysis of the Lyme disease vaccine.

  2002cites this paper